These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 31173910)

  • 1. Nitric oxide: a drug target for glaucoma revisited.
    Garhöfer G; Schmetterer L
    Drug Discov Today; 2019 Aug; 24(8):1614-1620. PubMed ID: 31173910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nitric oxide (NO): an emerging target for the treatment of glaucoma.
    Cavet ME; Vittitow JL; Impagnatiello F; Ongini E; Bastia E
    Invest Ophthalmol Vis Sci; 2014 Aug; 55(8):5005-15. PubMed ID: 25125670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting outflow facility in glaucoma management.
    Brubaker RF
    Surv Ophthalmol; 2003 Apr; 48 Suppl 1():S17-20. PubMed ID: 12852430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in glaucoma treatment and management: outflow drugs.
    Kaufman PL; Rasmussen CA
    Invest Ophthalmol Vis Sci; 2012 May; 53(5):2495-500. PubMed ID: 22562850
    [No Abstract]   [Full Text] [Related]  

  • 5. Nitric oxide-donating compounds for IOP lowering in glaucoma.
    Andrés-Guerrero V; García-Feijoo J
    Arch Soc Esp Oftalmol (Engl Ed); 2018 Jun; 93(6):290-299. PubMed ID: 29580758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of prostaglandin analogues on aqueous humor outflow pathways.
    Winkler NS; Fautsch MP
    J Ocul Pharmacol Ther; 2014; 30(2-3):102-9. PubMed ID: 24359106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nitric oxide donating anti-glaucoma drugs: advances and prospects.
    Mao YJ; Wu JB; Yang ZQ; Zhang YH; Huang ZJ
    Chin J Nat Med; 2020 Apr; 18(4):275-283. PubMed ID: 32402405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of TAK-639, a novel topical C-type natriuretic peptide analog, on intraocular pressure and aqueous humor dynamics in mice.
    Millar JC; Savinainen A; Josiah S; Pang IH
    Exp Eye Res; 2019 Nov; 188():107763. PubMed ID: 31421135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Influence of prostaglandins on aqueous humour dynamics and intraocular pressure].
    Raber T
    Klin Monbl Augenheilkd; 2005 Oct; 222(10):802-6. PubMed ID: 16240273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in glaucoma diagnosis and therapy for the next millennium: new drugs for trabecular and uveoscleral outflow.
    Kaufman PL; Gabelt B; Tian B; Liu X
    Semin Ophthalmol; 1999 Sep; 14(3):130-43. PubMed ID: 10790577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of 8-iso prostaglandin E2 on aqueous humor dynamics in monkeys.
    Wang RF; Lee PY; Mittag TW; Podos SM; Serle JB; Becker B
    Arch Ophthalmol; 1998 Sep; 116(9):1213-6. PubMed ID: 9747682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rho kinase inhibitors for glaucoma treatment - Review.
    Germano RA; Finzi S; Challa P; Susanna Junior R
    Arq Bras Oftalmol; 2015; 78(6):388-91. PubMed ID: 26677046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Rho Kinase Inhibitors on Intraocular Pressure and Aqueous Humor Dynamics in Nonhuman Primates and Rabbits.
    Toris CB; McLaughlin MA; Dworak DP; Fan S; Havens S; Zhan GL; Horan N; Prasanna G
    J Ocul Pharmacol Ther; 2016; 32(6):355-64. PubMed ID: 27266531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of action of bimatoprost (Lumigan).
    Brubaker RF
    Surv Ophthalmol; 2001 May; 45 Suppl 4():S347-51. PubMed ID: 11434937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacotherapies for glaucoma.
    Toris CB
    Curr Mol Med; 2010 Dec; 10(9):824-40. PubMed ID: 21091423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical models.
    Krauss AH; Impagnatiello F; Toris CB; Gale DC; Prasanna G; Borghi V; Chiroli V; Chong WK; Carreiro ST; Ongini E
    Exp Eye Res; 2011 Sep; 93(3):250-5. PubMed ID: 21396362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guanylate cyclase activators, cell volume changes and IOP reduction.
    Ellis DZ
    Cell Physiol Biochem; 2011; 28(6):1145-54. PubMed ID: 22179003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel nitric oxide releasing prostaglandin analog, NCX 125, reduces intraocular pressure in rabbit, dog, and primate models of glaucoma.
    Borghi V; Bastia E; Guzzetta M; Chiroli V; Toris CB; Batugo MR; Carreiro ST; Chong WK; Gale DC; Kucera DJ; Jia L; Prasanna G; Ongini E; Krauss AH; Impagnatiello F
    J Ocul Pharmacol Ther; 2010 Apr; 26(2):125-32. PubMed ID: 20415621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of nitric oxide in murine conventional outflow physiology.
    Chang JY; Stamer WD; Bertrand J; Read AT; Marando CM; Ethier CR; Overby DR
    Am J Physiol Cell Physiol; 2015 Aug; 309(4):C205-14. PubMed ID: 26040898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Novel therapeutic targets for reduction of intraocular pressure in primary open angle glaucoma].
    Mao WM; Liu Y; Wordinger YH; Clark AF; Pang IH
    Zhonghua Yan Ke Za Zhi; 2016 Jun; 52(6):471-5. PubMed ID: 27373575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.